SPDR S&P Pharmaceuticals ETF Rating $67.16 +0.34 (+0.51%) As of 04:10 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartDividendHeadlinesHoldingsOwnershipRatingsShort InterestBuy This Stock SPDR S&P Pharmaceuticals ETF Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.XPH Aggregate RatingModerate Buy 2.78Holdings in XPH have an aggregate rating of Moderate Buy based on 289 analyst ratings issued in the past year covering 25 companies (48.1% of the portfolio).XPH Aggregate Price Target$67.16High Prediction$67.16Average Prediction$67.16Low Prediction$67.16Holdings in XPH have an aggregate price target of $67.16 and a range of $67.16 to $67.16 covering 25 companies (48.1% of the portfolio).XPH Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy3 Buy rating(s)Moderate Buy20 Moderate Buy rating(s)Hold2 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by SPDR S&P Pharmaceuticals ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 25 XPH Holdings ExportWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings2.88%DFTXDefinium Therapeutics$45.98+5.3%2.3456 of 5 stars3.00$49.23 7.1%172.81%MBXMBX Biosciences$56.59-5.7%1.4105 of 5 stars2.77$60.22 6.4%13News CoverageAnalyst UpgradeGap Down2.05%ALMSAlumis$27.28-2.9%3.1004 of 5 stars2.83$40.30 47.7%122.04%ELVNEnliven Therapeutics$51.73+1.7%3.4091 of 5 stars2.86$69.17 33.7%7Positive NewsAnalyst Revision2.02%TRVITrevi Therapeutics$17.91+8.4%3.7378 of 5 stars3.00$22.67 26.6%11News CoveragePositive News2.01%AMLXAmylyx Pharmaceuticals$18.20+4.5%2.9559 of 5 stars2.90$24.25 33.2%10News CoverageInsider Trade1.98%ATAIAtai Beckley$5.67+14.1%3.7749 of 5 stars2.92$15.50 173.4%12Options Volume1.98%MANEVeradermics$109.85-0.3%2.8685 of 5 stars2.63$135.60 23.4%8Analyst Downgrade1.98%MAZEMaze Therapeutics$29.88+2.4%1.8815 of 5 stars3.00$66.00 120.9%11News Coverage1.95%LGNDLigand Pharmaceuticals$300.97-2.7%3.101 of 5 stars2.88$292.86 -2.7%8Positive News1.94%NKTRNektar Therapeutics$67.17-1.7%3.1504 of 5 stars2.73$149.63 122.8%11Positive News1.89%HROWHarrow$41.37-1.1%4.2854 of 5 stars2.64$69.43 67.8%111.85%CRNXCrinetics Pharmaceuticals$83.71+0.0%1.4504 of 5 stars2.29$78.27 -6.5%17Analyst Upgrade1.84%EWTXEdgewise Therapeutics$39.73-3.7%2.85 of 5 stars2.82$47.92 20.6%11News Coverage1.84%NUVBNuvation Bio$5.89+2.0%3.3443 of 5 stars2.64$12.38 110.3%111.83%LQDALiquidia$76.49+7.4%2.7038 of 5 stars2.82$68.88 -10.0%11Trending NewsInsider Trade1.77%EYPTEyepoint Pharmaceuticals$13.73-3.9%3.437 of 5 stars2.88$44.29 222.5%8News Coverage1.77%CORTCorcept Therapeutics$90.47+5.3%2.1027 of 5 stars2.75$88.83 -1.8%81.68%WVEWAVE Life Sciences$6.13+3.0%3.0546 of 5 stars2.87$26.41 330.9%15News CoveragePositive News1.67%AMRXAmneal Pharmaceuticals$16.69-2.9%2.473 of 5 stars2.71$15.80 -5.3%7News CoveragePositive NewsAnalyst Upgrade1.67%OCULOcular Therapeutix$9.70-1.8%3.222 of 5 stars2.79$25.11 158.9%141.66%ELANElanco Animal Health$25.56+1.7%3.5526 of 5 stars2.77$28.55 11.7%131.65%PCRXPacira BioSciences$25.01-2.1%2.3538 of 5 stars2.29$29.40 17.6%71.65%TARSTarsus Pharmaceuticals$56.11-5.4%2.7754 of 5 stars2.78$90.67 61.6%9Analyst Downgrade1.64%JNJJohnson & Johnson$253.70-1.6%4.4753 of 5 stars2.74$261.26 3.0%27Trending NewsUpcoming EarningsAnalyst Forecast This page (NYSEARCA:XPH) was last updated on 7/14/2026 by MarketBeat.com Staff. From Our PartnersTrump’s $250 Bill – See ImmediatelyFormer Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...Stansberry Research | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredTrump Admin to Pump $1 Billion into this “Off-the-Radar” AI StockThe U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...InvestorPlace | SponsoredHow much money does your next trade really require?If a stock trades at $300, most investors assume they need $300 per share. Sean Allison says that assumption m...Trade Thirsty | SponsoredThe only metrics you should watch as a day trader.Day traders and swing traders don't need the same metrics - and using the wrong ones costs you edge. After 40 ...The TradingPub | Sponsored60 years. Zero competitors.One company has spent 60 years developing an energy source the International Energy Agency estimates at 140 ti...Behind the Markets | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredSpaceX Opens Up 11% — Here’s What You Need to KnowSpaceX - ticker SPCX - just completed the biggest IPO in American history, raising $75 billion at a $1.8 trill...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SPDR S&P Pharmaceuticals ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share SPDR S&P Pharmaceuticals ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
